Isabelle Solassol
Overview
Explore the profile of Isabelle Solassol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cabello-Aguilar S, Vendrell J, Evrard S, Thomas Q, Roch B, Escudie F, et al.
Lab Invest
. 2025 Feb;
:104117.
PMID: 39986540
MET amplification (MET) is a noteworthy genomic alteration that can occur in patients with non-small cell lung cancer (NSCLC). It has been demonstrated to occur as a primary oncogenic driver...
2.
Vendrell J, Ban I, Solassol I, Audran P, Cabello-Aguilar S, Topart D, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37762485
Purpose: The introduction of PARP inhibitors (PARPis) as a treatment option for patients with high-grade serous ovarian cancer (HGSOC) modified the approach of testing worldwide. In this study, we aim...
3.
Vendrell J, Quantin X, Aussel A, Solassol I, Serre I, Solassol J
Transl Lung Cancer Res
. 2022 Jan;
10(11):4084-4094.
PMID: 35004240
Background: Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is highly selective for subclones in patients with non-small cell lung cancer (NSCLC). Unfortunately, all patients...
4.
Solassol I, Pinguet F, Quantin X
Biomolecules
. 2019 Nov;
9(11).
PMID: 31671561
Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized...
5.
Beganton B, Solassol I, Mange A, Solassol J
Expert Rev Proteomics
. 2019 Jul;
16(8):717-726.
PMID: 31269821
: The proteome is a dynamic system in which protein-protein interactions play a crucial part in shaping the cell phenotype. However, given the current limitations of available technologies to describe...
6.
Lafaille F, Solassol I, Enjalbal C, Bertrand B, Doulain P, Vappiani J, et al.
J Pharm Biomed Anal
. 2013 Nov;
88:429-40.
PMID: 24176748
EAPB0503, belonging to the imidazo[1,2-a]quinoxaline series, is an anticancer drug with antitumoral activity against a variety of tumors. Previous studies have shown that this drug undergoes demethylation and oxygenation reactions....
7.
Khier S, Gattacceca F, El Messaoudi S, Lafaille F, Deleuze-Masquefa C, Bompart J, et al.
Drug Metab Dispos
. 2010 Jul;
38(10):1836-47.
PMID: 20660102
For several years, our group has been developing quinoxalinic compounds. Two of them, N-methyl-1-(2-phenethyl)imidazo[1,2-a]quinoxalin-4-amine (EAPB0203) and 1-(3-methoxyphenyl)-N-methylimidazo[1,2-a]quinoxalin-4-amine (EAPB0503), have emerged as the most promising anticancer drugs. In the present work,...
8.
Khier S, Deleuze-Masquefa C, Moarbess G, Gattacceca F, Margout D, Solassol I, et al.
Eur J Pharm Sci
. 2009 Oct;
39(1-3):23-9.
PMID: 19854270
In spite of the development of new anticancer drugs by the pharmaceutical industry, melanoma and T lymphomas are diseases for which medical advances remain limited. Thus, there was an urgent...
9.
Charasson V, Hillaire-Buys D, Solassol I, Laurand-Quancard A, Pinguet F, Le Morvan V, et al.
Eur J Cancer
. 2009 Jun;
45(13):2391-401.
PMID: 19501504
Folate, a vitamin of the B group involved in one-carbon group metabolism, plays an important role in DNA synthesis and methylation. Several polymorphisms in the genes involved in folate uptake...
10.
Khier S, Moarbess G, Deleuze-Masquefa C, Solassol I, Margout D, Pinguet F, et al.
J Sep Sci
. 2009 Apr;
32(9):1363-73.
PMID: 19399864
Since several years, our group developed quinoxalinic compounds. Among the synthesized compounds, in the imidazo[1,2-a]quinoxaline series, EAPB0203 has shown interesting activities both on melanoma and lymphoma. The structure of EAPB0203...